$Bionano Genomics(BNGO)$ closed the day trading at $1.14 up 5.56% from the previous closing price of $1.08. In other words, the price has increased by $+0.0600 from its previous closing price. On the day, 4219872 shares were traded. BNGO stock price reached its highest trading level at $1.1700 during the session, while it also had its lowest trading level at $1.0900.
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Ratios:
For a better understanding of BNGO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 4.40. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on January 05, 2023, initiated with a Sector Outperform rating and assigned the stock a target price of $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 when Linney Yvonne sold 20,000 shares for $3.62 per share. The transaction valued at 72,402 led to the insider holds 0 shares of the business.
BARKER DAVID L bought 10,000 shares of BNGO for $16,000 on May 16. The Director now owns 13,894 shares after completing the transaction at $1.60 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 12.78 while its Price-to-Book (P/B) ratio in mrq is 1.36.
Stock Price History:
Over the past 52 weeks, BNGO has reached a high of $4.35, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is 1.5450, while the 200-Day Moving Average is calculated to be 1.9239.
Shares Statistics:
Over the past 3-months, BNGO traded about 6.54M shares per day on average, while over the past 10 days, BNGO traded about 6.49M shares per day. A total of 296.95M shares are outstanding, with a floating share count of 291.38M. Insiders hold about 1.82% of the company’s shares, while institutions hold 27.30% stake in the company. Shares short for BNGO as of Jan 12, 2023 were 53.22M with a Short Ratio of 57.65M, compared to 48.76M on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 17.93% and a Short% of Float of 17.94%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.12, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.43 and -$0.45 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.44, with 3 analysts recommending between -$0.41 and -$0.47.
Revenue Estimates
5 analysts predict $8.06M in revenue for the current quarter. It ranges from a high estimate of $8.3M to a low estimate of $7.7M. As of the current estimate, Bionano Genomics Inc.’s year-ago sales were $6.3M, an estimated increase of 27.90% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $9M, an increase of 58.00% over than the figure of $27.90% in the same quarter last year. There is a high estimate of $10.26M for the next quarter, whereas the lowest estimate is $7.9M.
A total of 5 analysts have provided revenue estimates for BNGO’s current fiscal year. The highest revenue estimate was $27.89M, while the lowest revenue estimate was $27.3M, resulting in an average revenue estimate of $27.65M. In the same quarter a year ago, actual revenue was $17.98M, up 53.80% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $44.64M in the next fiscal year. The high estimate is $60.31M and the low estimate is $38.19M. The average revenue growth estimate for next year is up 61.40% from the average revenue estimate for this year.
source：dwinnex
Comments